JPMorgan downgraded Blueprint Medicines (BPMC) to Neutral from Overweight with a price target of $129, down from $130, after Sanofi (SNY) announced its intention to acquire Blueprint for $9.1B in equity value and up to $9.5B including a contingent value right. The firm cites the deal for the downgrade with the expected close in Q3.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint Medicines downgraded to Perform from Outperform at Oppenheimer
- Blueprint Medicines downgraded to Sector Perform from Outperform at Scotiabank
- Blueprint Medicines downgraded to Hold from Buy at Needham
- Morning Movers: Trump to bump steel tariffs, pharma companies announce deals
- Blueprint Medicines downgraded to Neutral from Outperform at Wedbush